In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
Jan 8 (Reuters) - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic ...
Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...
Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...
Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks. On January 13, 2026, an announcement came regarding ...
Jan 13 (Reuters) - U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to ...
Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...
Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...
On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...
Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback